https://www.selleckchem.com/pr....oducts/LY2603618-IC-
≥40 mg q2w (38.8% vs. 26.9%, p = .0418). DAS28-4/ESR remission rate improved from 21.7% (36/166) at baseline to 74.7% (112/15 at week 24.Conclusions Adalimumab was well tolerated and had acceptable safety and effectiveness in patients with JIA in the real-world setting.Background Epidemiological data suggest a link between psychological stress and increased cardiovascular disease risk; however, the underlying mechanisms remain incompletely understood. The purpose of this investigation was to directly examine the influence of d
Like
Comment
Share
